Filing Flows › Cardlytics (CDLX) › R&D spending
Cardlytics (CDLX) R&D spending by quarter
Cardlytics' R&D spending was $3.7M in Q3 2026 (third quarter 2026), -33% from Q2 2026. Over the last 7 quarters it ranged from $3.7M (Q3 2026) to $11.7M (Q1 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $3.7M | -33% | -58% |
| Q2 2026 | $5.5M | -14% | -51% |
| Q1 2026 | $6.4M | -19% | -45% |
| Q4 2025 | $8.0M | -9% | — |
| Q3 2025 | $8.8M | -22% | — |
| Q2 2025 | $11.3M | -4% | — |
| Q1 2025 | $11.7M | — | — |
Q3 2026 at a glance
Cardlytics, Q3 2026: revenue $32.9M (-30% year over year), operating margin -16.5%, net loss $8.9M, operating cash flow −$5.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is Cardlytics' R&D spending?
Cardlytics' R&D spending was $3.7M in Q3 2026 (third quarter 2026), -33% from Q2 2026.
How has Cardlytics' R&D spending changed?
Over the last 7 quarters it ranged from $3.7M (Q3 2026) to $11.7M (Q1 2025).